CNTA - Centessa Pharmaceuticals plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2020
31/12/2019
Total revenue
0
0
0
0
Operating expenses
Research development
155,083
155,083
9,301
4,263
Selling general and administrative
55,200
55,200
1,139
790
Total operating expenses
210,283
210,283
10,440
5,053
Operating income or loss
-210,283
-210,283
-10,440
-5,053
Interest expense
7,033
7,033
378
118
Total other income/expenses net
362
362
155
105
Income before tax
-216,954
-216,954
-10,663
-5,061
Income tax expense
-747
-747
-
-
Income from continuing operations
-216,207
-216,207
-10,663
-5,061
Net income
-216,207
-216,207
-10,663
-5,061
Net income available to common shareholders
-216,207
-216,207
-10,663
-5,061
Basic EPS
-
-2.31
-0.15
-0.07
Diluted EPS
-
-2.31
-0.15
-0.07
Basic average shares
-
93,401
70,891
70,891
Diluted average shares
-
93,401
70,891
70,891
EBITDA
-
-209,921
-10,285
-4,937